KRYS

KRYS

Krystal Biotech Exceeds Expectations with Q3 2026 Performance

Krystal Biotech has made a significant impact in the third quarter of 2026, showcasing the company's growth and commitment to innovation. The biotech firm reported a substantial increase in revenue, reaching $127.3 million, which marks a 30% rise from the same period last year. Additionally, the company

KRYS

Krystal Biotech Delivers Strong Q2 Performance, Advances Pipeline and Commercial Growth

Krystal Biotech, a biotechnology company specializing in rare and serious diseases, has announced impressive results for its second quarter of 2026. In a recent conference call, the company's leadership highlighted significant progress across both commercial and clinical programs. The key takeaway from Q2 is that Krystal Biotech made